Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer-birthed Ziarco raises $33m for skin drugs

This article was originally published in Scrip

Executive Summary

A company formed by Pfizer's former head of allergy and respiratory research in Sandwich, UK, has raised $33.1m in a series B round to fund development of novel candidates to treat atopic dermatitis and psoriasis. Ziarco, headed by Mike Yeadon, will use the funds to complete proof of concept Phase II trials of its two lead candidates.

You may also be interested in...



Atopic Dermatitis: Ziarco Hopes Oral Therapy Will Trump Injectable Biologics

UK biotech Ziarco’s orally active histamine H4-antagonist shows potential in atopic dermatitis in proof-of-concept studies, and the firm may seek capital for further studies before it is Phase III ready.

Q3 Review: Editor’s Picks Of Scrip's Top Stories

From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.

Topics

Related Companies

UsernamePublicRestriction

Register

SC026873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel